Kinetic seals $1.7bn deal with LifeCell and tags on new biosurgery division
This article was originally published in Clinica
Advanced wound care company Kinetic Concepts is to buy tissue repair product manufacturer LifeCell in a cash transaction worth $1.7bn, a move that will enable Kinetic to consolidate its presence in the fast-growing biosurgery market.
You may also be interested in...
Allergan has agreed to acquire Acelity's LifeCell division for $2.9bn. The deal will give Allergan entry to the regenerative medicine sector and expand its aesthetics portfolio, while the substantial cash consideration should console Acelity after ditching plans for an IPO.
Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.